Human H-Ficolin Inhibits Replication of Seasonal and Pandemic Influenza A Viruses

Anamika Verma, Mitchell White, Vinod Vathipadiekal, Shweta Tripathi, Julvet Mbianda, Micheal Ieong, Li Qi, Jeffery K. Taubenberger, Kazue Takahashi, Jens C. Jensenius, Steffen Thiel and Kevan L. Hartshorn

*J Immunol* 2012; 189:2478-2487; Prepublished online 30 July 2012; doi: 10.4049/jimmunol.1103786
http://www.jimmunol.org/content/189/5/2478
Human H-Ficolin Inhibits Replication of Seasonal and Pandemic Influenza A Viruses

Anamika Verma,* Mitchell White,* Vinod Vathipadiekal,† Shweta Tripathi,* Julvet Mbianda,* Micheal Ieong,* Li Qi,‡ Jeffery K. Taubenberger,‡ Kazue Takahashi,§ Jens C. Jensenius,*, Steffen Thiel,*, and Kevan L. Hartshorn*

The collectins have been shown to have a role in host defense against influenza A virus (IAV) and other significant viral pathogens (e.g., HIV). The ficolins are a related group of innate immune proteins that are present at relatively high concentrations in serum, but also in respiratory secretions; however, there has been little study of the role of ficolins in viral infection. In this study, we demonstrate that purified recombinant human H-ficolin and H-ficolin in human serum and bronchoalveolar lavage fluid bind to IAV and inhibit viral infectivity and hemagglutination activity in vitro. Removal of ficolins from human serum or bronchoalveolar lavage fluid reduces their antiviral activity. Inhibition of IAV did not involve the calcium-dependent lectin activity of H-ficolin. We demonstrate that H-ficolin is sialylated and that removal of sialic acid abrogates IAV inhibition, while addition of the neuraminidase inhibitor oseltamivir potentiates neutralization, hemagglutinin inhibition, and viral aggregation activity of H-ficolin. We demonstrate that H-ficolin is sialylated and that removal of sialic acid abrogates IAV inhibition, while addition of the neuraminidase inhibitor oseltamivir potentiates neutralization, hemagglutinin inhibition, and viral aggregation caused by H-ficolin. Pandemic and mouse-adapted strains of IAV are generally not inhibited by the collectins surfactant protein D or mannose binding lectin because of a paucity of glycan attachments on the hemagglutinin of these strains. In contrast, H-ficolin inhibited both the mouse-adapted PR-8 H1N1 strain and a pandemic H1N1 strain from 2009. H-ficolin also fixed complement to a surface coated with IAV. These findings suggest that H-ficolin contributes to host defense against IAV. The Journal of Immunology, 2012, 189: 2478–2487.

The collectins surfactant protein D (SP-D), surfactant protein A (SP-A), and mannose-binding lectin (MBL) have been shown to contribute to innate defense against influenza A virus (IAV) infection. The ficolins resemble MBL in their overall structure, calcium-dependent binding to pathogens, and ability to fix complement in an Ab-independent manner (1).

In humans, there are three different ficolin forms (H-, L-, and M-ficolin) and one form of MBL (2). H-ficolin has a shorter collagen domain than the other two ficolins. H-ficolin exists in blood at a mean level of ~20 µg/ml (reported ranges of 8–80 µg/ml) (3, 4), which greatly exceeds that of the other ficolins (L-ficolin, 3.4 µg/ml; M-ficolin, 1.4 µg/ml) or MBL (1.1 µg/ml) (5). H-ficolin is also produced by alveolar type II cells and ciliated bronchial epithelial cells in the lung and has been demonstrated to be present in bronchoalveolar lavage fluid (BALF) (6), although the concentration in BALF has not been determined. Subjects have been described who are homozygous for a truncated version of H-ficolin and essential absence of this protein in serum (7, 8). The major clinical manifestation of the adult patient was recurrent respiratory infections, whereas the other two patients were neonates with necrotizing enterocolitis. Therefore, it is likely that H-ficolin has a role in innate immunity.

The interactions of ficolins with bacteria have been well studied, but there are limited data regarding ficolin interactions with viruses. L-Ficolin has been shown to bind to envelope proteins of hepatitis C virus (HCV) and to fix complement on HCV-infected hepatocytes (9). Recently L-ficolin was also shown to inhibit influenza A virus (IAV) in vitro and in mice (10). Porcine ficolin has been shown to neutralize porcine reproductive and respiratory syndrome virus (11). In both of these cases, the antiviral effect was related to recognition of N-linked glycans on the viral envelope proteins by the ficolin. Recent studies have also shown that chimeric proteins containing the N-terminal domains of ficolins and the carbohydrate recognition domain of MBL strongly inhibit Ebola virus and IAV (12, 13); however, in this case the reaction is mediated by the binding of the carbohydrate recognition domain of MBL to virus associated carbohydrates. The recognition domain of the ficolins differs from that of the collectins, which are C-type lectins; it has some homology to domains of fibrinogen, and is thus named a fibrinogen-like domain. Ficolins recognize acetylated compounds (both N-acetylated sugars and other acetylated molecules), whereas MBL and other collectins preferentially bind to terminal carbohydrate groups with horizontal OH groups at the 3 and 4 positions (e.g., mannose-rich glycans on pathogens) (14).

In this study, we focused mainly on H-ficolin because of its probable role in respiratory infections. We demonstrate that H-ficolin neutralizes various strains of IAV through a distinct mechanism that does not involve their calcium-dependent lectin activity. This feature allows the ficolins to inhibit viral strains not inhibited well by collectins.
Materials and Methods

Virus preparations
Philippines 82/H3N2 (Phil82) strain was provided by Dr. E. Margot Anders (University of Melbourne, Melbourne, Australia). The PR-8 (1934 H1N1) strain was provided by Jon Abramson (Wake Forest University, Winston-Salem, NC). These IAV strains were grown in the chorioallantoic fluid of 10-day-old chicken eggs and purified on a discontinuous sucrose density gradient as described previously (15). The virus was dialyzed against PBS to remove sucrose, sectioned into aliquots, and stored at −80°C until needed. After thawing, the viral stocks contained ~5 × 10^8 infectious focus forming units per milliliter. The California 2009 H1N1 strain was derived by reverse genetics and grown in Madin–Darby canine kidney (MDCK) cells.

Protein preparations and other reagents
Recombinant H-ficolin was produced and purified as described previously (4). In addition, H-ficolin was purified from human serum in complex with the MBL-associated serine protein (MASP2) as described (4). L-Ficolin was purified as described (14). M-ficolin was produced and purified as described (16). Pentraxin-3 was purchased from Abcam (ab85335). Recombinant human MBL was a gift from Dr. Kazue Takahashi (Massachusetts General Hospital, Boston, MA), and human alveolar proteinosis derived SP-A was a gift from Dr. Frank McCormack (University of Cincinnati School of Medicine, Cincinnati, OH). Oseltamivir was provided by Roche.

Measurement of H-ficolin levels in human serum and BALF
Human serum and BALF were obtained from healthy volunteer donors under approval from the Institutional Review Board of the Boston University School of Medicine. The degree of dilution of BALF from the two donors was similar because the urea concentrations of these samples were 430 and 490 μg/mL prior to concentration. The level of H-ficolin in the serum or BALF was obtained using a commercial ELISA kit designed for this purpose (Hyculin Biotechnology). Each sample was measured at various dilutions, and the average of results from these dilutions was calculated. A standard curve was used to give H-ficolin levels. To deplete ficolin from serum or BALF, the fluids were incubated with N-acetyl-D-galactosamine-agarose (Sigma, catalog no. A2787) overnight at 4°C as described (17). Ficolin bound to N-acetyl-D-galactosamine-agarose was removed by centrifugation at 3500 × g for 10 min. Effective removal of H-ficolin was confirmed by ELISA.

Binding of H-ficolin to IAV
Binding of H-ficolin was assessed by solid-phase ELISA. Plates were coated with 10 μg/mL IAV in coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) overnight at 4°C with PBS containing 2.5% (v/v) BSA (fraction V, fatty acid free, and low endotoxin, A8806; Sigma-Aldrich) as background control. After washing three times with PBS with 2 mM calcium and magnesium (PBS++) the plates were blocked with PBS containing 2.5% BSA for 3 h. The plates were then incubated with ficolin and then washed with PBS++ with 0.02% Tween 20, followed by addition of an Ab against H-ficolin (Santa Cruz, catalog no. SC55202) diluted in the same buffer. Incubation of IAV with ficolins was performed in PBS++.

Assessment of ficolins by Western blot or glycocalyx blot
Human serum (30 μL of a 1:100 dilution per well) or BALF (30 μL of concentrated fluid per well) was subjected to SDS-PAGE followed by transfer to nitrocellulose and treatment with anti-H-ficolin Ab. For ficolin blotting, 10 μL recombinant H-ficolin or MBL was added directly to nitrocellulose, and labeled Sambucus nigra agglutinin (SNA) or Maackia amurensis agglutinin (MAA) lectins (Roche Applied Science) were added. Binding was detected by use of anti-digoxigenin–alkaline phosphatase peroxidase conjugate and anti-digoxigenin–alkaline phosphatase conjugate (Roche) per the manufacturer’s instructions. SNA and MAA lectins detect (α2,3)- and (α2,6)-linked sialic acids, respectively.

Hemagglutination inhibition assay
Hemagglutinin (HA) inhibition was measured by serially diluting ficolins or other host defense protein preparations in round-bottom, 96-well plates (Sarocylinder U-Vinyl plates; Costar, Cambridge, MA) using PBS++ as a diluent (18). After adding 25 μL IAV, giving a final concentration of 40 HA units per ml or 4 HA units/well, the IAV–protein mixture was incubated for 15 min at room temperature, followed by addition of 50 μL of a type O human erythrocyte suspension. The minimum concentration of protein required to fully inhibit the hemagglutinating activity of the viral suspension was determined by noting the highest dilution of protein that still inhibited hemagglutination. The inhibition of HA activity in a given well is demonstrated by the absence of the formation of an erythrocyte pellet. If no inhibition of HA activity was observed at the highest protein concentration used, then the value is expressed as greater than the maximal protein concentration.

Measurement of viral aggregation
Viral aggregation was measured by assessing light absorbance by stirred suspensions of IAV. The virus was diluted using a Perkin Elmer Lambda 35 ultraviolet/Vis spectrophotometer at 350 nm. In addition, viral aggregation was assessed using electron microscopy as described (19).

Fluorescent focus assay of IAV infectivity
MDCK cell monolayers were prepared in 96-well plates and grown to confluence. These layers were then infected with diluted IAV preparations for 45 min at 37°C in PBS and washed with PBS to remove IAV–protein mixture. The reaction was stopped using 1 N sulfuric acid. The OD was measured at 430 and 490 nm before and after incubation with tetramethylbenzidine as a substrate (Bio-Rad).

Complement fixation assay
To deplete ficolin from human serum, the level of H-ficolin in the BALF from the two IAV-infected cell cultures was determined by noting the highest dilution of protein that still inhibited hemagglutination. The degree of dilution of BALF from the two donors was similar. The California 2009 H1N1 strain was derived by reverse genetics and grown in Madin–Darby canine kidney (MDCK) cells.

Measurement of viral RNA
RNA for the viral M protein was measured using real-time PCR. A549 cells were infected with Phil 82 virus strain incubated for 30 min at 37°C with or without various doses of ficolin. RNA extraction was done at 45 min and 24 h after infection using Magmax viral RNA isolation kit (Applied Biosystems, Carlsbad, CA) per the manufacturer’s instructions. Both lysed cells and cell supernatant were used for extraction. Viral RNA was also extracted from different concentrations of virus with known infectious units in milliliters (as defined by the fluorescent foci assay, see above) which was used as standard series. RNA was reverse transcribed using TaqMan reverse transcription reagents (Applied Biosystems). The reaction mix and the cycle conditions were established according to the manufacturer’s instructions. For real-time PCR, primers specific for IAV M protein (forward 5’-AGA CCA ATC CTG TCA CCT CTGA-3’ and reverse 5’-CTC TCA TCG TCT ACT-3’) were used. The primers and TaqMan-labeled probes with nonfluorescent minor groove binder (MGB) moieties were designed manually using the Primer Express software version 3.0 (Applied Biosystems) and were also synthesized by Applied Biosystems. The assay sequences were examined for specificity by nucleotide BLAST. The experiment was performed in a 7500 real-time PCR system (Applied Biosystems) using volume of 20 μl containing 2 μl template cDNA, 0.1 μM primer 0.25 μM of 6-FAM dye-labeled TaqMan MGB probe (6-FAM-ATT GTT GAC GCT CGT CCA GMB), and 1× TaqMan Universal PCR master mix (Applied Biosystems). Thermal cycling proceeded at 50°C for 2 min, 95°C for 10 min followed by 40 cycles of 95°C for 15 s, 60°C for 1 min, and 72°C for 30 s.

Confocal microscopy
MDCK cells were preincubated with the PR-8 strain of IAV, H-ficolin (10 μg/mL), or H-ficolin and oseltamivir (10 μg/mL) for 45 min, followed by washing and fixation using 1% paraformaldehyde. Wheat germ agglutinin Oregon Green 488 (4 μg/mL) and DAPI 350 were used to stain the cell membrane and nucleus respectively. The virus was Alexa Fluor 594 labeled. Confocal pictures were taken with a Zeiss LSM510 (LSEB) at ×10 resolution.

Complement fixation assay
Fixation of complement component C4 on to ELISA plates coated with IAV or acetylated BSA was tested as described (4) using the H-ficolin/MASP-2 complex purified from human serum. Briefly, 96-well plates were coated overnight in sodium bicarbonate buffer with either 5 μg/mL acetylated BSA (Sigma, catalog no. B2518) or 10 μg/mL Phil82 IAV at 4°C. The next morning, plates were washed three times with wash buffer (10 mM Tris, pH 7.4, 120 mM NaCl, 10 mM CaCl2, 0.05% Tween 20) and blocked with blocking buffer (0.1% BSA in 10 mM Tris, pH 7.4, 120 mM NaCl, 10 mM CaCl2) for 2 h and shaken at 37°C. Plates were then washed three times. H-ficolin/MASP was combined with C4 complement in PBS buffer (4 μM barbital buffer, pH 7.5, 145 mM NaCl, 2 mM CaCl2, 1 mM MgCl2) and added to the plate for 1.5 h. Plates were then washed and labeled with rabbit anti-human C4c (1 h at 37°C) followed by peroxidase-labeled streptavidin. The Journal of Immunology 2479
(Kirkegaard and Perry Laboratories, catalog no. 14-30-00). Plates were washed three times between each Ab, and HRP levels were detecting using One-Step ELISA (Fisher Scientific). Plates were read at 450 nm with a wavelength correction of 540 nm on a POLARstar OPTIMA plate reader (BMG Labtech).

Statistics
Statistical comparisons were made using Student paired, two-tailed t test or ANOVA with post hoc test (Tukey). ANOVA was used for multiple comparisons to a single control.

Results
**Human H-ficolin binds to IAV**

We first tested the ability of recombinant human H-ficolin to bind to IAV strains of IAV. Fig. 1A shows that recombinant H-ficolin bound to the Phil82, PR-8, and Cal09 strains in a dose-dependent manner. Unexpectedly, binding of H-ficolin to IAV was increased in buffer lacking calcium and magnesium (Fig. 1B). Fig. 1C demonstrates that H-ficolin present in human serum also bound to IAV (PR-8 and Phil82 strains used in this case). Human BALF has also been reported to contain H-ficolin (6). We measured the level of H-ficolin in BALF using ELISA. The mean level of H-ficolin obtained in BALF samples from two healthy volunteers was 102 ± 2 ng/ml. This BALF was concentrated 5-fold prior to assay. Presumably the concentration of H-ficolin in alveolar lining fluid substantially exceeds the levels present in BALF. As shown in Fig. 2A, H-ficolin in BALF also bound to IAV as measured ELISA. As an additional means of testing binding of H-ficolin in serum and BALF to IAV, we preincubated IAV (PR-8 strain) with human serum or BALF, followed by centrifugation of the fluids for 15 min at 13,000 × g. We have previously shown that collectins induce viral aggregation such that centrifugation of collectin-IAV mixtures in this manner results in pelleting of the virus (21). This procedure resulted in precipitation of H-ficolin out of serum (Fig. 1D) or BALF (Fig. 2B). This again confirms that IAV binds to H-ficolin present in human serum and BALF.

**FIGURE 1.** Binding of recombinant and human serum H-ficolin to IAV. (A) ELISA plates were coated with three IAV strains (California 2009 H1N1, PR-8 1934 H1N1, and Philippines 1982 H3N2) and then incubated with increasing concentrations of recombinant H-ficolin. Background binding to BSA-coated plates was subtracted from the values shown. There was significant binding (*p < 0.05) of H-ficolin to all viruses at all the doses shown. (B) Binding of H-ficolin to the PR-8 strain of IAV in the presence or absence of calcium and magnesium. Binding was significantly greater (**p < 0.05) in the absence of calcium and magnesium. (C) The results of incubation of various dilutions of human serum with similar ELISA plates, followed by Ab detection of bound H-ficolin. Again, there was significant binding of H-ficolin at all dilutions shown, although binding to PR-8 was significantly greater than binding to Phil82. Results are mean ± SEM of four experiments. (D) A Western blot of H-ficolin in serum. In this experiment the serum was incubated with the PR-8 strain of IAV or in control buffer, followed by centrifugation to pellet the virus. Supernatant and pellet samples (resuspended in the same amount of buffer) were analyzed by Western blot. This experiment is representative of three similar experiments.
by washing off the remaining virus and then adding H-ficolin or MBL (Fig. 5B). Using this method, there was still some inhibition of infectivity, but the effect was reduced compared with either preincubating the cells or the virus with ficolin. This finding suggests that H-ficolin mainly acts through binding to virus and possibly cells prior to viral internalization.

We also used quantitative PCR to assess whether H-ficolin inhibits viral attachment or uptake to A549 cells. To do this, we measured the amount of viral copies in homogenates of the cells after a 45-min infection period and extensive washing of cells to remove free virus. As shown in Fig. 6A, H-ficolin did not reduce the amount of cell associated virus measured after 45 min. However, H-ficolin inhibited synthesis of RNA of the viral M protein in the cells or in the cell free supernatant after 24 h of infection as shown in Fig. 6B (for supernatant) or 6C (for cell associated virus).

**H-ficolin inhibits hemagglutination activity of IAV in a non–calcium-dependent manner**

We tested the ability of H-ficolin to inhibit HA activity caused by two strains of virus, Phil82 H3N2 and PR-8. As shown in Table I, H-ficolin inhibited Phil82, although the activity was considerably reduced as compared with that of MBL. However, when the assay was performed in buffer lacking calcium or in buffer containing EDTA, the activity of H-ficolin was strongly enhanced, whereas that of MBL was abrogated. H-ficolin had considerably stronger HA inhibitory activity against the PR-8 strain of IAV than against Phil82, and this activity was again further increased in buffer lacking calcium and magnesium or containing EDTA. As shown in Fig. 1B, binding of H-ficolin to IAV was also increased in the absence of calcium and magnesium, perhaps accounting for the increased HA inhibition. As reported previously, MBL did not inhibit the PR-8 strain under any condition (24). This finding is consistent with the known mechanism of inhibition by MBL, which involves calcium-dependent binding to glycans on the viral surface.

**FIGURE 2.** Binding of H-ficolin in human BAL fluid to IAV. Binding was demonstrated using two methods. (A) BALF was incubated with IAV coated plates and binding of H-ficolin in BALF was detected by ELISA. Binding was significant ($p < 0.05$ for all tested dilutions of BALF). Results are mean ± SEM of four experiments. (B) Virus (PR-8 strain) was incubated with BALF for 45 min followed by centrifugation to pellet virus particles. The presence of H-ficolin in the supernatant and pellet was demonstrated by Western blot. Results are representative of three experiments.

**FIGURE 3.** Neutralization of IAV strains by ficolins. Viral neutralization was tested using a fluorescent focus assay and MDCK cells as described. The number of fluorescent (infected) cells was counted after 7 h of infection. Diluted viral strains were incubated with control buffer (PBS with 2 mM calcium and magnesium) or different concentrations of ficolins, MBL, or SP-A, followed by addition of these samples to cells. The multiplicity of infection for these experiments was 1. M-, L-, and H-ficolin were all tested for their ability to inhibit the Phil82 (A) or PR-8 (B) strains of IAV. (C) H-ficolin was tested for its activity against Cal09. All ficolins caused significant inhibition of all IAV strains at the concentrations tested ($p < 0.05$ versus control). (D) An additional set of experiments in which the activity of H-ficolin was compared with that of human SP-A (native protein from BAL) or recombinant human MBL. H-ficolin caused significantly greater inhibition of Cal09 than either SP-A or MBL at the concentrations tested. Results are mean ± SEM of four experiments. *Significant difference by ANOVA.
The PR-8 strain lacks glycan attachments on the head region of the HA, whereas the Phil82 strain has multiple such glycans (25).

Role of ficolin-associated sialic acid-rich glycan in IAV inhibition

Several innate inhibitors of IAV (e.g., SP-A, pentraxin, gp340) work by presenting a decoy sialic acid-rich ligand to which the viral HA binds (26, 27). This process, called γ-inhibition, is not calcium dependent. In our previous studies with other γ-inhibitors of IAV (e.g., mucins, SP-A or gp-340), addition of the neuraminidase inhibitor, oseltamivir, led to potentiation of antiviral activity (28, 29). When H-ficolin was combined with oseltamivir, a significant increase in HA-inhibitory activity occurred (Table I). This suggests a role for binding of the viral HA to sialylated glycans on H-ficolin in HA inhibition.

The ficolins have N-linked glycan attachments in their fibrinogen-like domain (30). To determine whether these are sialylated, we performed glycan blotting of the ficolins. As shown in Fig. 7A, all three ficolins showed the presence of α(2,3)- and α(2,6)-linked glycans, whereas MBL (which does not have any N-linked glycan attachment site) did not. To confirm the role for ficolin-associated sialic acids in viral inhibition, we treated H-ficolin with neuraminidase and then repurified the protein. This treatment completely abrogated the HA inhibitory activity of H-ficolin (Fig. 7B). Neuraminidase treatment caused the expected small decrease in the apparent m.w. of H-ficolin, but did not result in degradation of the protein (Fig. 7C).

BALF causes inhibition of HA activity of IAV (Table II). BALF was much less effective at inhibiting HA activity of the PR-8 strain than the Phil82 strain. This reflects the importance of SP-D in inhibiting seasonal strains of IAV as reported previously (22, 25). Note, however, that there is some inhibition of the fully SP-D–resistant PR-8 strain that was strongly potentiated by oseltamivir, suggesting that this inhibition is mediated to a significant extent by γ-inhibitors. The viral neutralizing activity of BALF for Phil82 and PR-8 strains of IAV was also increased in the presence of oseltamivir (Fig. 8A, 8B). There are multiple γ-inhibitors in BALF, some of which have been shown to inhibit IAV, including pentraxin-3 (PTX3) and gp340 (26, 31). Of interest, recent studies demonstrated specific binding of PTX3 to M- and L-ficolins and

FIGURE 4. Effect of ficolin depletion on viral neutralizing activity of human serum or BALF. Normal donor human serum or BALF was incubated with N-acetyl-D-galactosamine-agarose as described to remove ficolins and the serum or BALF before or after depletion were compared for viral neutralizing activity using the infectious focus assay and PR-8. The serum or BALF was preincubated with the virus for 45 min followed by titration on MDCK cells. (A) Results obtained with serum from one donor at the indicated dilutions. (B) Results obtained with BALF from two separate donors (labeled 1 and 2). The BALF was used either undiluted or at 1:1 dilution in PBS as indicated. The results are mean ± SEM of three experiments with each dilution of serum or BALF. *Depleted BALF or serum had significantly less neutralizing activity than the untreated samples.

FIGURE 5. Effect of adding H-ficolin to MDCK cells before or after virus infection on neutralizing activity. The neutralization assay was performed as in Fig. 3, except that in (A) the MDCK cells were preincubated with the ficolin prior to infection with IAV, and in (B) ficolin was added to MDCK cells after viral infection. (In Fig. 3, virus was preincubated with ficolins prior to infection of MDCK cells). Preincubation of MDCK cells with H-ficolin caused comparable inhibition of viral infection with the three indicated viral strains as in Fig. 3. Results with human MBL are shown for comparison. H-ficolin caused significantly greater inhibition of the PR-8 strain than MBL, whereas MBL caused significantly greater inhibition of the Phil82 strain than H-ficolin at 4 μg/ml. Results in (B) show that the addition of H-ficolin or MBL after viral infection for 45 min caused much less inhibition than found in (A) or in Fig. 3. Note, however, that H-ficolin still caused significant inhibition compared with control using this method (p < 0.05 for all viruses at 4 μg/ml). Results are mean ± SEM of four experiments. *Differences as assessed by ANOVA.
synergistic host defense activities between these proteins (32). H-ficolin and PTX3 caused cooperative inhibition of HA activity (Table II) and infectivity of PR-8 and Phil82 (Fig. 8A, 8B). M-ficolin had a similar effect (Fig. 8C). Therefore, it is possible that H-ficolin in BALF contributes to inhibition of IAV through direct effects and through interactions with other inhibitors.

We performed confocal microscopy to directly evaluate how H-ficolin alone or in presence of oseltamivir alters interaction of IAV with A549 cells within 45 min of infection. As shown in Fig. 8B, H-ficolin alone caused what appears to be a reduced number of viral particles associated with cells at this time point. As shown in Fig. 5, quantitative PCR did not show reduced total viral RNA associated with the cells under these conditions. This finding suggested that ficolin might be reducing particle numbers through viral aggregation. It is difficult to assess this at this level of magnification unless the aggregates are large (e.g., SP-D causes formation of large viral aggregates that are easily visible by fluorescent microscopy) (Ref. 21 and data not shown); however, the viral particles appeared somewhat larger in H-ficolin treated samples versus control. Of interest, when H-ficolin and oseltamivir were used together, viral particle sizes appeared larger than with H-ficolin alone (Fig. 8B, right panel).

**H-ficolin causes viral aggregation**

Given the results obtained with confocal microscopy, we used more sensitive techniques to assess viral aggregation. H-ficolin induced aggregation of IAV as assessed by electron microscopy or light absorbance assays (Fig. 9A, 9B, respectively). On the light transmission assay, aggregation induced by H-ficolin alone was subtle, although comparable to that induced by MBL (not shown). As in the case of defensins (19), aggregation caused by H-ficolin was most clearly evident on electron microscopy. The addition of oseltamivir along with H-ficolin dramatically increased aggregation as assessed by light absorbance.

**H-ficolin fixes complement to IAV-coated surfaces**

The PR-8 strain of IAV was coated onto the surface of ELISA plates as for the ELISA assay shown in Fig. 1. These plates were then incubated with H-ficolin/MASP-2 complexes purified from human serum as described (4). As shown in Fig. 10, there was dose-related deposition of the C4 component of complement onto the virus-coated surface. The extent of complement deposition was less than the amount seen on the acetylated BSA surface, which served as the positive control.

### Table I. Hemagglutination inhibition by H-ficolin or MBL

<table>
<thead>
<tr>
<th>Viral Strain</th>
<th>Buffer</th>
<th>H-Ficolin</th>
<th>Oseltamivir</th>
<th>Oseltamivir + H-Ficolin</th>
<th>MBL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phil82 H3N2</td>
<td>PBS + Ca(^{2+}) and Mg(^{2+})</td>
<td>2.25 ± 0.5(^a)</td>
<td>0.001 ± 0</td>
<td>0.001 ± 0</td>
<td>0.001 ± 0</td>
</tr>
<tr>
<td>PBS, no Ca(^{2+}) and Mg(^{2+})</td>
<td>0.15 ± 0.004(^a)</td>
<td>&gt;5</td>
<td>&gt;5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PBS + EDTA</td>
<td>0.23 ± 0.02(^a)</td>
<td>&gt;5</td>
<td>&gt;5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PR-8 H1N1</td>
<td>PBS + Ca(^{2+}) and Mg(^{2+})</td>
<td>1.17 ± 0.6(^a)</td>
<td>0.32 ± 0.25(^c)</td>
<td>&gt;5</td>
<td></td>
</tr>
<tr>
<td>PBS, no Ca(^{2+}) and Mg(^{2+})</td>
<td>0.55 ± 0.13(^b)</td>
<td>&gt;5</td>
<td>0.13 ± 0.11(^c)</td>
<td>&gt;5</td>
<td></td>
</tr>
<tr>
<td>PBS + EDTA</td>
<td>0.55 ± 0.22(^b)</td>
<td>&gt;5</td>
<td>0.06 ± 0.05(^c)</td>
<td>&gt;5</td>
<td></td>
</tr>
</tbody>
</table>

Results are expressed as mean ± SEM in micrograms per milliliter of ficolin protein resulting in inhibition of 40 HA units of the indicated strains of IAV. The concentration of oseltamivir added was 10 μg/ml. For H-ficolin, \(n\) = 4; for MBL, \(n\) = 3 or 4, except in case of Phil82 in PBS with calcium and magnesium, where \(n\) = 2.

\(^a\)Significantly reduced compared with control buffer (\(p < 0.05\)).

\(^b\)Significantly reduced compared with control buffer or H-ficolin in PBS with calcium and magnesium, where \(n\) = 2.

\(^c\)Significantly reduced compared with H-ficolin without oseltamivir.
A neuraminidase treated H-ficolin. Results in (with the virus samples and infectious focus assay. Only untreated H-ficolin neuraminidase-treated H-ficolin, or neuraminidase alone were pre-oligosaccharide attachments) was tested as well. (Materials and Methods using SNA and MAA as sialic acid detecting molecules as described in Materials and Methods. For comparison, MBL (which has no N-linked oligosaccharide attachments) was tested as well. (B) Untreated H-ficolin, neuraminidase-treated H-ficolin, or neuraminidase alone were pre-incubated with PR-8 or Phil82 IAV followed by infection of MDCK cells with the virus samples and infectious focus assay. Only untreated H-ficolin significantly inhibited viral infectivity. (C) SDS-PAGE of untreated and neuraminidase treated H-ficolin. Results in (B) are mean ± SEM of four experiments. *p < 0.01 versus control.

Discussion

In this study, to our knowledge, we demonstrate for the first time that H-ficolin has antiviral activity against IAV. We also measure the levels of H-ficolin in BALF for the first time, to our knowledge, and show that H-ficolin in human serum and BALF bind to IAV. Importantly, H-ficolin effectively inhibited the 2009 pandemic H1N1 strain of IAV, which is resistant to other innate inhibitors, including SP-D, MBL, and pentraxin. We finally show that H-ficolin/MASP-2 complexes fix complement to IAV-coated surfaces. Overall, our findings suggest that H-ficolin has a role in innate defense against IAV in the airway and could contribute to the rarity of viremia in IAV infection. Pan et al. (10) recently demonstrated that L-ficolin inhibits IAV and that treatment of IAV with L-ficolin protects mice against effects of IAV infection. Our findings differ somewhat from those of Pan et al.; they showed that inhibition mediated by L-ficolin was calcium dependent and presumably mediated by the lectin property of L-ficolin. We cannot readily account for this difference, but we performed extensive experiments to confirm that the inhibition mediated by H-ficolin is not mediated by its lectin property. The mechanism of neutralization caused by IAV was rather that of a γ-inhibitor (i.e., a glycosylated protein that provides a decoy sialylated ligand for binding by the viral HA). Binding and inhibition by γ-inhibitors is not calcium dependent. Unexpectedly, we found that binding and inhibition by H-ficolin was actually increased in the absence of calcium, which differs from findings with PTX3 where absence of calcium did not alter anti-IAV activity (26).

Other important γ-inhibitors of IAV include SP-A, gp-340, mucins, α2-macroglobulin, and pentraxin (26, 27, 29, 33). Porcine SP-D is distinctive because it acts as a combined β- and γ-inhibitor (34). The effectiveness of γ-inhibitors depends in part on the extent to which the viral neuraminidase is able to cleave these sialic acids and release the virus from attachment to the inhibitor. As an example, mucins are relatively ineffective as inhibitors of IAV because the sialic acid ligands on mucins are readily cleaved by the viral neuraminidase. As a result, incubation of IAV with the combination of mucins and the neuraminidase inhibitor oseltamivir results in a marked increase in viral inhibition compared with that achieved with either alone (28, 29). Other γ-inhibitors like SP-A, porcine SP-D, gp-340, pentraxin, and ficolins have at least partial resistance to the activity of neuraminidase because they have antiviral activity in the absence of oseltamivir. In the case of SP-A, however, this intrinsic antiviral activity can be further increased by oseltamivir. We show that oseltamivir increases neutralizing, HA inhibitory, and aggregating activity of H-ficolin. With or without oseltamivir, the HA inhibitory and neutralizing activity of H-ficolin alone was much greater than for either mucins or SP-A (e.g., HA inhibitory concentrations for H-ficolin are ∼5-fold lower than those of SP-A) (29). We propose that H-ficolin has a role in host defense against IAV in vivo (as has been demonstrated for SP-A), and that one of the mechanisms through which oseltamivir is beneficial in treating IAV is through potentiating the activity of γ-inhibitors, including H-ficolin.

SP-D has the major role in the innate inhibitory activity of BALF for seasonal IAV strains (18, 31). As a result, BALF causes much less inhibition of SP-D resistant strains such as PR-8; this is important because pandemic IAV strains are generally resistant to inhibition by SP-D as well. There is some level of inhibition of such strains by BALF, and this is increased significantly in the presence of oseltamivir, as shown in Table II. A significant part of this activity appears to be mediated by ficolins based on our ficolin depletion results. The contribution of H-ficolin to the antiviral activity of BALF could be mediated by H-ficolin acting independently or via cooperative interactions of H-ficolin with other inhibitors. For example, we show that H- and M-ficolins have cooperative HA-inhibitory effects when combined with PTX3. M-ficolin has been shown to bind to PTX3, whereas H-ficolin does not (32, 35); however, M-ficolin did not have a significantly

![Figure 7](http://www.jimmunol.org/)
greater cooperative interaction with PTX3 than H-ficolin. This finding suggests that the binding of PTX3 to M-ficolin does not significantly contribute to combined antiviral effects. Because both PTX3 and ficolins resemble C1q and fix complement, further study of the combined effects on complement fixation in the presence of IAV would be interesting (32). We propose that g-inhibitors provide an important level of innate protection against IAV strains that are able to bypass the action of SP-D or MBL. The activity of g-inhibitors for specific viral strains depends on the specific types of sialic acid linkage present on the proteins (34, 36). In general the HA of avian or mouse adapted IAV strains have preferential binding to a(2,3)-linked sialic acids, whereas human strains prefer binding to a(2,6)-linked sialic acids. These preferences coincide with the type of sialic acid linkages found, respectively, on avian (or mouse) versus human epithelia targeted by the virus. The collectins, other than SP-A and porcine SP-D, de-

FIGURE 8. Effect of oseltamivir or PTX3 on viral neutralizing activity of H-ficolin or on effects of H-ficolin on viral attachment or uptake by A549 cells as assessed with confocal microscopy. (A–C) Results of infectious focus assays using H- or M-ficolin alone or combined with either oseltamivir (5 μg/ml) or PTX3 (5 μg/ml). Results are mean ± SEM of four experiments. Addition of both oseltamivir and PTX3 significantly increased neutralizing activity compared with H-ficolin alone at either the 2.5- or 5-μg/ml concentration of H-ficolin. This was true both for the Phil82 (A) or PR-8 (B) strains of IAV. PTX3 or oseltamivir alone did not reduce viral infectivity in this assay. The results for PTX3 are shown at the zero concentration of ficolins in the curves labeled PTX3. PTX3 significantly increased the neutralizing activity of M-ficolin as shown in (C). (D) Confocal microscopic pictures of virus (red) after 45 min incubation with A549 cells (cell membrane green and nucleus blue). The multiplicity of infection for the confocal experiments was 200 (i.e., higher than in infectious focus and quantitative PCR assays). Results are representative of three experiments. Nuclei are labeled with DAPI350 (blue), cell membranes with WGA Oregon green, and virus with Alexa Flour 594 (red).

FIGURE 9. Viral aggregation induced by H-ficolin or MBL. (Top) Representative (of four experiments) electron microscopic images of PR-8 IAV alone (control) versus IAV pretreated with the indicated concentrations of H-ficolin or MBL. In these experiments, 10 μg/ml H-ficolin caused a similar degree of viral aggregation as MBL. (Bottom) The ability of H-ficolin to cause viral aggregation was also tested by light absorbance assay. In this assay, increased light transmission results from viral aggregation. This assay is less sensitive for detecting viral aggregation than electron microscopy; however, 20 and 40 μg/ml of H-ficolin did cause significant increase in light transmission 2 min after addition to the viral suspension. Addition of oseltamivir (10 μg/ml) during incubation of IAV with H-ficolin resulted in much more pronounced and sustained viral aggregation. No aggregation was seen with oseltamivir alone or with the PR-8 virus alone (black diamonds, bottom). Results in the bottom panel are mean ± SEM of four experiments.

FIGURE 10. H-ficolin/MASP-2 complexes fix complement in presence of IAV. ELISA plates were coated with IAV as in Fig. 1. H-ficolin/MASP-2 complexes were purified from human serum and incubated with the surface bound IAV as described in Materials and Methods. Complement fixation was detected using Ab to complement component C4. H-ficolin caused dose-related deposition of C4 onto the viral surface (n = 5). As a positive control, 2 μg/ml of the H-ficolin/MASP-2 complex was incubated with wells coated with acetylated BSA. This resulted in fixation of complement as reported (mean ± SEM OD450 for C4 was 1.2 ± 0.1). *p < 0.05 versus IAV-coated plates incubated with complement in the absence of H-ficolin.
pend on the presence of glycans on viral envelope proteins for their antiviral activity (37). High mannose glycans on the viral HA protein are most important for inhibition by MBL, SP-D, or the bovine serum collectins (conglutinin, CL43, and CL46) (38). Because the activity of γ-inhibitors is not dependent on viral envelope protein glycosylation, they have activity against strains that are resistant to MBL or SP-D. In fact, γ-inhibitors appear to have greater activity against some hypoglycosylated viral strains (e.g., PR-8) than against strains like Phi82 that have abundant glycans on the HA (21). This finding could reflect the fact that the addition of glycans to the globular domain of the HA reduces HA binding affinity for sialylated ligands. This appears to be the case for H-ficolin, which has substantially greater inhibitory activity for the PR-8 strain. In this case of PR-8 virus, however, it could also depend on the presence of α(2,3)-linked sialic acids on the γ-inhibitor, because PR-8 is highly selective for this type of sialic acid linkage. The ficolins expressed both types of sialic acid linkage, and this might account for their ability to inhibit both the human seasonal strain Phi82 and the mouse-adapted PR-8 strain.

Known pandemic strains of IAV isolated over the past 100 y all had reduced glycosylation of their HA compared with seasonal H1N1 and H3N2 strains (22). The ficolins are of particular interest in that they retain activity against the pandemic Calic H9N1 strain. This strain is not inhibited by SP-D or MBL effectively and requires significantly increased concentrations of SP-A for inhibition (23). Furthermore, potentaxin also did not inhibit this strain (23). It will be of great interest to determine whether ficolins inhibit other pandemic or avian strains (e.g., H5N1).

The ability of collectins and defensins to induce viral aggregation contributes to their viral neutralizing activity. Ficolins resemble the collectins MBL and SP-A on a structural basis because of similarities in their oligomeric structure and collagen domains. In fact, replacement of the N-terminal and collagen domains of MBL with those of L-ficolin results in chimeric molecules that have equal or greater viral aggregating and neutralizing activity than MBL (12, 13). As noted in the introduction, subjects with H-ficolin deficiency with increased susceptibility to influenza have been reported (7, 8). It is tempting to speculate that individuals lacking or with reduced levels of H-ficolin may also be more susceptible to IAV infection. Susceptibility to IAV infection could also result in more frequent bacterial respiratory infections because IAV predisposes to bacterial infection.

Disclosures

The authors have no financial conflicts of interest.

References


